TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Superficial Cervical Plexus Block for Shoulder Pain After Lung Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subjects who clinically consented to elective thoracotomy or video-assisted thoracoscopic surgery (VATS) under general anesthesia and epidural analgesia~* ages between 18 and 75 years~Exclusion Criteria:~* inability to perform thoracic epidural~* violation of protocol (e.g., administration of medication that does not comply with the study protocol)~* subject has change of mind~* surgery has to be repeated~Non-inclusion Criteria:~* subject refusal~* non-English speaking~* previous chronic or neuropathic pain~* previous chronic use of opioids~* history of psychiatric disorder~* allergy to local anesthetic~* previous ipsilateral thoracotomy or VATS~* prior history of shoulder pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Controls (Type: NO_INTERVENTION): Subjects enrolled in this group will only have a line drawn on the side of their neck for superficial cervical plexus block, but we will not perform the injection. The subjects will not be aware whether they received an intra-operative block or not. In addition, neither the Post-Anesthesia Care Unit nurse nor the providers involved in the post-operative care will be aware of subjects group assignment.
- Superficial Cervical Plexus Block (Type: ACTIVE_COMPARATOR): Subjects enrolled in this group will have a line drawn and will receive a superficial cervical plexus block at the end of the surgery just prior to emergence from anesthesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Participating in HSCT or cGVHD protocols and willing to participate in this study concurrently;~Diagnosed with oral cGVHD stomatitis confirmed by surgical biopsy results;~Oral ulceration present~Able to understand and sign protocol informed consent;~Ages 18 to 80 years of age.~EXCLUSION CRITERIA:~Pregnant or lactating females;~For the proof of concept study, females who are not surgically sterilized by means of hysterectomy or tubal ligation;~For the main study, females of childbearing potential who do not agree to the use of two forms of highly effective contraception for at least four weeks prior, during, and for four weeks following the last dose of study drug;~Sexually active males who do not agree to the use of a latex condom while receiving study drug and for four weeks following the last dose of study drug;~Unwilling to follow precautions for use of thalidomide;~Unable to demonstrate appropriate use of study medication;~Concurrent use of non-protocol-related medications confounding assessment of the inflammatory response (antihistamines, non-steroidal anti-inflammatory drugs);~Allergic reaction to thalidomide;~Pre-existing oral infection, which might maximize the possibility of an infection or sepsis contributing to a drug-related adverse event;~Unwilling or unable to forego concurrent treatment for mucosal lesions and/or related oral pain (including topical steroids, viscous lidocaine, topical anti-fungals);~Requiring addition of new systemic therapy including thalidomide, steroids, or radiation therapy;~Use of sedatives (including CNS depressants);~Absolute neutrophil count (ANC) less than 750/mm(3)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Thalidomide gel (Type: EXPERIMENTAL): Thalidomide gel 20 mg applied topically 4 times daily for 4 weeks to a maximum of 3 target oral ulcers
- Placebo (Type: EXPERIMENTAL): Placebo gel with no Thalidomide applied topically 4 times daily for 4 weeks to a maximum of 3 target oral ulcers

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: GM1 Prophylaxis for WBRT Related Cognitive Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18-75,with histological affirmative breast cancer ,and over 4 brain metastases ,need for WBRT suggested by radiotherapy oncologist ;~* Estimated survival time over 6months;~* Abundant hematological function:Absolute Neutrophil Count≥2×109/L ;platelet count≥100×109/L and hemoglobulin≥9 g/dL;~* Abundant liver function：total bilrubin≤ULN；ASTandALT≤2.5ULN；AKP≤5ULN~* Can cope with HVLT-RDR and ADAS-Cog evaluation~* No prior therapy could induce neurological damage,within 4 weeks~* No more that 1 degree peripheral neuropathy or any other diseases or symptoms that could hinder the evaluation of neurological AE~* No more treatment or nursing is allowed after enrolling this trail~* Written Informed Consent signed~Exclusion Criteria:~* PS score over 2,and estimated no attenuation by WBRT~* Women with pregnancy or breast feeding~* Unwilling to contraception measurement~* Abnormal baseline impairment of cognitive impairment~* Allergy to experiment agents or components~* Unsuitable to GM1 treatment, evaluated by investigators~* Active infection~* RT dose over 30Gy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Experimental arm(GM1) (Type: EXPERIMENTAL): This arm will be treated with GM1.
- Control arm (Type: PLACEBO_COMPARATOR): This arm will be treat with blank placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Post-market Surveillance Study With the HYPERION Hip Endoprosthesis System in Defect Reconstruction

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient age at least 18 years~* Fully conscious and capable patients~* Signed informed consent~* Stationary treatment~* Merle d'Aubigné \< 12 Points, WOMAC Score \> 25 Points~* Patients with at least one of the following indications:~Indications for primary hip replacement:~* Non-inflammatory diseases of the joints such as osteoarthritis and avascular necrosis (head necrosis)~* Rheumatoid arthritis~* Functional deformities~* Provision of non-endoprosthetic previous operations of the hip joint (e.g., transposition osteotomies)~* Treatment of pseudarthrosis, femoral neck and trochanter fractures, as well as fractures of the proximal femur affecting the head, which can not be treated by other techniques~Revision THA:~* Revision of endoprosthesis-treated hips as a result of septic or aseptic loosening, sub- and periprosthetic fractures or material failure (eg fracture of the prosthesis)~* Bridging of large bone defects (precondition: suitable proximal bone situation for a stable anchorage), i.e. for tumors~Exclusion Criteria:~* Infections~* Patients under 18 years~* Pregnant or breastfeeding patients~* Known alcohol abuse (at least 20 g alcohol per day for women and at least 40 g per day for men) or drug abuse~* Legal incapacity or restricted capacity~* Participation in another clinical trial within the last 30 days or planned participation in another clinical trial within the next 3 months~* Patients who are unable to attend to follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants delivered at a gestational age of less than or equal to 35 6/7 weeks (Preterm) being treated with high velocity nasal insufflation therapy for the management of respiratory distress syndrome~2. Patients that clinically require SpO2 maintenance within the target range of 90-95%~3. A need for supplemental oxygen as demonstrated by a required FiO2 \> 0.25 at enrollment~4. Requiring a flow rate of greater than 2 L•min-1 such that the assumed inspired oxygen fraction matched delivered oxygen fraction (definition of HVNI).~5. A minimum of 6 manual FiO2 adjustments in the 24hr period prior to trial enrollment.~6. Willing/Able to complete informed consent.~Exclusion Criteria:~1. Current patient weight of \<1000g or \>3500g at time of study~2. Major congenital abnormalities~3. Hemodynamic instability, defined as being outside of a normotensive range based on an infant's individual characteristics by clinician~4. Persistent unresolved apnea defined as: requiring 6 stimulations or more per 6 hours~5. Seizures~6. Ongoing sepsis~7. Meningitis~8. Clinician's concern regarding stability of the infant

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Automated Control (OAM) (Type: EXPERIMENTAL): In this arm, FiO2 levels delivered via high-velocity nasal insufflation therapy (Vapotherm Precision Flow) will be adjusted by the Oxygen Assist Module (OAM) to keep the infants pulse oxygen saturation within a target range (90-95%). Clinical staff will have the ability to override FiO2 levels when required, and instructed to do so.
- Manual Control (Manual) (Type: ACTIVE_COMPARATOR): In this arm, FiO2 levels delivered via high-velocity nasal insufflation therapy (Vapotherm Precision Flow) will be manually adjusted by clinical staff to keep infants' oxygen saturation between 90-95%.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients more than 40 years old~2. HCCs diagnosed by AASLD image criteria or pathology~3. HCCs in BCLC advanced stage, with portal vein thrombosis (VP3 or VP4) or extrahepatic metastasis~4. Not suitable or failed to locoreginal treatments for HCC~5. Child-Pugh score = or \< 6~6. ECOG performance status (PST) 0-2~7. Serum bilirubin \< 2 mg/dL and prothrombin time (PT) prolongation \< 3 seconds~8. Will receive sorafenib therapy~9. Life expectancy \> 3 months~10. Will follow the pregnancy prevention protocol~Exclusion Criteria:~1. HCC is considered for curative therapy~2. HCC with brain metastasis~3. History of systemic therapy for HCC~4. Indications for statin use, such as hyperlipidemia in cardiovascular diseases~5. Any local treatment for HCC within 4 weeks~6. Any active gastrointestinal bleeding within 4 weeks~7. Liver transplant history or concomitant immunosuppressive therapy~8. Concurrent any other malignancy~9. Allergy to sorafenib or statins~10. Pregnancy or lactation~11. Serum AST or ALT \> 5x upper limit of normal~12. Known HIV infection~13. eGFR \< 30 ml/min~14. Abnormal medical conditions that are unsuitable for study, such as uncontrolled hypertension, coronary arterial disease, or arrhythmia

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Statin treated group (Type: EXPERIMENTAL): None
- Control group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of an Online Mindfulness Based Programme for Informal Caregivers of People With Chronic Illnesses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be 18 years of age and over~* Provide unpaid care to an adult or child with a chronic illness~* Not suffer from a severe mental illness~* Be ready to commit to the course at this point in their lives.~Exclusion Criteria:~* Caregivers who are under the age of 18 years.~* Caregivers who have a serious mental illness, such as severe anxiety/depression.~* Caregivers who are in receipt of current and regular treatment from a psychologist or psychiatrist.~* Caregivers with an active or recent physical addiction to alcohol or drugs.~* Caregivers who are already engaged in similar research.~* Caregivers who have already participated in mindfulness based stress reduction (MBSR) or MBCT training.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Usual care (Type: NO_INTERVENTION): No intervention
- Mindfulness based Stress Reduction (Type: EXPERIMENTAL): This is an active intervention The MBSR programme is delivered online with weekly telephone and email contact from a trained mindfulness teacher. Participants are encouraged to practice mindfulness exercises and homework between sessions. The online programme was developed be a trained mindfulness teacher.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of the Lockdown Due to the COVID Pandemic in French Wilson's Disease Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Wilson's disease patient~* Patient over 12 years of age~* Patient followed by doctors from the Wilson national reference centers (Paris, Lyon, Toulouse, Besançon, Bordeaux, Rennes, Marseilles, Tours, Lille )~* Patients hospitalized or seen in outpatient consultation (or teleconsultation) during the first confinement and at the end of the last one~* Non-opposition of participation in the study and for minor patient non-opposition of one of the two holders of the exercise of parental authority~Exclusion criteria :~* Patient subject to a legal protection (tutorship)~* Patient or patient representative not wishing to answer questions

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Intravenous Cannabis Reduce Postoperative Nausea and Vomiting (PONV)?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-III~* elective open and laparoscopic surgery \>1hour~Exclusion Criteria:~* ambulatory surgery~* pregnancy, breast feeding~* \>ASA III~* BMI \>35~* antipsychotic, antiemetic, cytostatic therapy~* major cardiovascular, renal, hepatic, central nervous system disease~* current chronic cannabis consumption and hard drug abuse~* schizophrenia~* preoperative nausea and vomiting, vestibular disease~* not speaking german or french~* refusal to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Receives 0.125mg/kg THC before emergence
- 2 (Type: PLACEBO_COMPARATOR): Receives NaCl before emergence

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Talent Converter Post-Approval Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subjects in whom a vessel access procedure was/will be performed with the attempted introduction of the Talent Converter Stent Graft for use according to the indications for use in the Instructions for Use (IFU) 0-365 days prior to enrollment.~2. Subjects who are able to understand the nature of the study and give voluntary informed consent.~3. Subjects who are available for follow-up visits.~4. Subjects 18 years of age or older.~Exclusion Criteria:~1. Subjects in whom an attempted treatment was/will be performed with the Talent Converter Stent Graft other than (i.e., primary AUI) as a secondary endovascular intervention for patients having received prior endovascular repair with either a Talent or AneuRx bifurcated stent graft.~2. Subjects in whom an attempted treatment was/will be performed with the Talent Converter Stent Graft as a secondary endovascular intervention for patients having received prior endovascular repair with a bifurcated stent graft other than (i.e., Cook Zenith or Gore Excluder) a Talent or AneuRx bifurcated stent graft.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants with Successful Secondary Endovascular Treatment (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 18F-FMAU PET/CT in Imaging Patients With Advanced Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have been diagnosed with a malignancy/tumor/cancer, including but not limited to: brain tumor, breast cancer, lung cancer, esophageal cancer, lymphoma, or sarcoma~* Have one or more tumors visualized by conventional PET-CT, CT or magnetic resonance imaging (MRI) prior to the PET FMAU study; PET-CT should be within one week prior to 18F-FMAU~Exclusion Criteria:~* Have undergone chemotherapy or radiation therapy within the previous one month~* Women of childbearing potential, unless they have had a negative urine beta human chorionic gonadotropin (betaHCG) within the previous 24 hours of the procedure~* Patients who have had surgery at the site of the suspected lesion within 1 month

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (fluorine F 18 d-FMAU PET/CT scan) (Type: EXPERIMENTAL): Patients receive fluorine F 18 d-FMAU IV followed by PET/CT prior to start of cancer treatment. Patients may undergo 2 additional scans at one week prior to second course of chemotherapy and after completion of cancer treatment depending on cancer type.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Invasive cervical carcinoma (squamous, adeno or adenosquamous histologies, small cell histology excluded)~* age \>18years~* International Federation of Gynecology and Obstetrics ((FIGO) stage IB2, IIA-IVA, FIGO stages IA, IB1 with positive pelvic lymph nodes or parametria either on imaging techniques or pathologically involved at the time of surgery.~patients undergoing surgical removal of the cervix and uterus are not eligible, parametria either on imaging techniques or pathologically involved at the time • Performance status Eastern Cooperative Oncology Group(ECOG)/World Health Organisation (WHO) 0, 1 or \>/=70%respectively White Blood count (WBC) ≥ 3,000, platelets ≥ 100,000, Absolute Neutrophil Count (ANC) \> 1500~• serum bilirubin ≤ 1.5 times upper limit of normal, transaminase ≤ 3 times upper limit of normal calculated creatinine clearance \>60milliliters (mls)/liter ( Cockcroft) OR creatinine \</= 2.0mgs% paraaortic adenopathy absent or 1.5 centimeter (cm) in greatest dimension on Computerised Tomography (CT) or Magnetic Resonance Imaging (MRI) scan;~No history of myocardial infarction in the last 6 months no symptomatic angina pectoris negative pregnancy test in patients under 50 Hemoglobin \>12.0 Gd/dl or \>7.5 mmo;/L with transfusion if needed written written informed consent~Exclusion criteria:~surgical resection of the primary tumor (i.e. Total abdominal hysterectomy (TAH)/ Bilateral salpingoophorectomy (BSO)~* patients with pacemakers or implanted defibrillators~* patients with significant metallic foreign bodies (i.e. hip replacements, bone metallic rods,orthopedic plates, etc.)~* prior radiotherapy or chemotherapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients received cisplatin IV and concurrently underwent hyperthermia treatment over 60-90 minutes on day 1. Patients also underwent external beam radiation therapy once daily on days 1-5. Treatment repeated weekly for 5-6 weeks in the absence of disease progression or unacceptable toxicity. After completion of chemoradiotherapy and hyperthermia, patients underwent brachytherapy to the cervix for 2-3 days.
- Arm II (Type: ACTIVE_COMPARATOR): Patients received cisplatin and undergo external beam radiation therapy (and brachytherapy) as in arm I.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues